statistiche ricercatore

Continente	#
NA - Nord America	435
AS - Asia	382
EU - Europa	224
SA - Sud America	59
AF - Africa	15
Continente sconosciuto - Info sul continente non disponibili	15
OC - Oceania	1
Totale	1.131

Città	#
Singapore	75
Ashburn	68
Chandler	44
Dallas	41
Dublin	37
San Jose	36
Santa Clara	33
Hong Kong	27
Ho Chi Minh City	21
Los Angeles	20
Beijing	15
Shanghai	12
Frankfurt am Main	11
Hanoi	11
Johannesburg	11
Boardman	10
Buffalo	10
Council Bluffs	9
Rome	9
Lauterbourg	8
New York	8
Philadelphia	6
Ann Arbor	5
Milan	5
Princeton	5
Tianjin	5
Columbus	4
Dearborn	4
London	4
Newark	4
Phủ Lý	4
Tokyo	4
Vienna	4
Bologna	3
Chicago	3
Florence	3
Guangzhou	3
Hefei	3
Hải Dương	3
Modena	3
Moscow	3
Nuremberg	3
Shenzhen	3
Tashkent	3
Wilmington	3
Amsterdam	2
Baghdad	2
Boston	2
Bremen	2
Cambridge	2
Cuenca	2
Denver	2
Divinópolis	2
Feira de Santana	2
Guarulhos	2
Izmir	2
Jakarta	2
Kagoya	2
Lahore	2
Osasco	2
Praia Grande	2
Quận Bình Thạnh	2
Reggio Emilia	2
Waanrode	2
Aalborg	1
Abbotsford British Columbia	1
Aberdeen	1
Addis Ababa	1
Al Hillah	1
Annandale	1
Antwerp	1
Astana	1
Asunción	1
Athens	1
Atlanta	1
Baku	1
Bari	1
Barra do Piraí	1
Bexley	1
Borgomanero	1
Brasília	1
Brussels	1
Bến Tre	1
Canoinhas	1
Cao Lanh	1
Carpi	1
Casselberry	1
Castellaneta	1
Catania	1
Chaguanas	1
Chapecó	1
Chennai	1
Cianorte	1
City of London	1
Córdoba	1
Da Nang	1
DeLand	1
Des Moines	1
Elk Grove Village	1
Erbil	1
Totale	680

Nome	#
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project	141
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache	138
Cluster headache in relation to different age groups	134
Clinical features of cluster headache in relation to age of onset: results from a retrospective study of a large case series	129
Migraine with typical aura: clinical features and their relationship with sex and age of onset. Results from the analysis of a large case series	113
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II)	112
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures	106
Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine	94
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study	88
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study	76
Totale	1.131

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	45	0	0	0	3	0	18	0	4	3	0	4	13
2022/2023	143	16	21	7	8	8	18	1	12	45	2	1	4
2023/2024	52	2	10	0	1	5	12	0	1	4	5	2	10
2024/2025	185	5	10	5	5	36	23	6	5	27	16	10	37
2025/2026	617	33	21	104	61	105	43	41	31	76	29	64	9
2026/2027	48	28	20	0	0	0	0	0	0	0	0	0	0
Totale													1.131